ABSINasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Absci Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.54+0.29 (+3.52%)
Close on Oct 19, 2026
- Market cap
- $1.34B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-4297.0%−4018.8 pts over 5 years
Net margin
-4113.7%−3813.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -38.2% | -21.3% | -10.1% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 22.0% | -62.5% | |
| Return on assets | – | – | -53.6% | |
| Current ratio | – | 7.25 | 6.57 | |
| Debt to equity | – | -0.05 | 0.00 | |
| Net debt to EBITDA | – | 5.55× | 0.18× | |
| Interest coverage | – | -21.0× | -575.7× | |
| Capex to revenue | – | 45.6% | 39.5% | |
| Diluted shares | – | 15M | 137M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Absci generated $371.90M from operations and spent $56.59M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$371.90M
Used
$56.59M
Capital expenditure$56.59M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4113.7%
×Asset turnover0.01×
×Equity multiplier1.17×
=Return on equity, FY2025-62.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4113.7% | 0.01× | 1.17× | -62.5% |
| FY2024 | -2274.1% | 0.02× | 1.21× | -58.0% |
| FY2023 | -1933.6% | 0.02× | 1.19× | -49.1% |
| FY2022 | -1825.4% | 0.02× | 1.17× | -32.8% |
| FY2021 | -2111.3% | 0.02× | 1.86× | -73.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$115.18M
- Cash generatingOperating cash flow above zero-$92.93M
- Return on assets improvedROA up on the prior year-47.4% → -53.9%
- Earnings backed by cashOperating cash flow above net income-$92.93M vs -$115.18M
- Less leverageLong-term debt to assets fell0.6% → 0.0%
- Better liquidityCurrent ratio rose4.67 → 6.57
- No dilutionShare count did not rise110M → 137M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.01